Heterocyclic amides as kinase inhibitors

1. A compound according to Formula (I):

wherein:

X is CH 2;

Q is a 5-membered heteroaryl ring moiety, wherein the heteroaryl ring moiety contains one heteroatom, which heteroatom is a sulfur ring heteroatom;

Q 4 is C;

each R is independently selected from (C 1 -C 6 )alkyl;

n is 0, 1, 2 or 3;

R 5 is H;

A is a 5-6 membered heteroaryl ring comprising one to three heteroatoms, wherein the heteroatom is nitrogen, and wherein the carbonyl moiety and L are substituted 1,3 on ring A;

L is CH 2; and

B is phenyl;

or a pharmaceutically acceptable salt, or a tautomer, thereof.

2. The compound according to claim 1 which is

or a pharmaceutically acceptable salt, or a tautomer, thereof.

3. The compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is selected from the group consisting of:

5-benzyl-N-(6,8-dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-thieno[3,4-b]azepin-3-yl)-4H-1,2, 4-triazole-3-carboxamide;

5-benzyl-N-(5-oxo-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-6-yl)-4H-1,2, 4-triazole-3-carboxamide; and

5-benzyl-N-(2-methyl-5-oxo-5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepin-6-yl)-4H-1,2, 4-triazole- 3-carboxamide;

or a tautomer thereof.